January 6, 2014
Shionogi and UK-based AstraZeneca (AZ) revised the royalty payment for the hyperlipidemia treatment Crestor (rosuvastatin), which AZ pays to Shionogi, on January 1. Shionogi will now receive a smaller royalty percentage rate for Crestor from 2014 onward, compared to the...read more